Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.81 USD
Change Today +0.04 / 5.19%
Volume 7.0K
DMPI On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

delmar pharmaceuticals inc (DMPI) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/27/14 - $1.10
52 Week Low
08/12/14 - $0.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

delmar pharmaceuticals inc (DMPI) Related Businessweek News

No Related Businessweek News Found

delmar pharmaceuticals inc (DMPI) Details

DelMar Pharmaceuticals, Inc. focuses on the discovery and development of medicines with the potential to treat cancer patients who have failed modern targeted or biologic therapy. Its principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China. DelMar Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Vancouver, Canada.

4 Employees
Last Reported Date: 05/7/15
Founded in 2010

delmar pharmaceuticals inc (DMPI) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $72.0K
Co-Founder, Chief Scientific Officer and Dire...
Total Annual Compensation: $60.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $60.0K
Compensation as of Fiscal Year 2014.

delmar pharmaceuticals inc (DMPI) Key Developments

Del Mar Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015

Del Mar Pharmaceuticals Inc. reported earnings results for the third quarter and nine months ended March 31, 2015. For the third quarter, the company reported net and comprehensive loss $1,649,136 or $0.04 per share against net and comprehensive loss $3,198,607 or $0.10 per share a year ago. The company reported a net loss of approximately $4,050,000, or a net loss per share of $0.11 compared to a net income of approximately $2,730,000, or a net income per share, of $0.09 for the nine months ended March 31, 2014. The income from 2014 was due to the revaluation of derivative liability.

Del Mar Pharmaceuticals Inc. Plans to Present Data Supporting the Development of VAL-083 in Refractory Glioblastoma Multiforme and Non-Small Cell Lung Cancer at the American Society of Clinical Oncology Annual Meeting

Del Mar Pharmaceuticals Inc. announced that it will be presenting new data related to the development of lead product candidate VAL-083 (dianhydrogalactitol) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29-June 2, 2015, in Chicago, Illinois. The company's clinical data from its Phase I/II study of VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme (GBM), entitled, 'Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma will be presented at ASCO during the Central Nervous System Tumors poster session on June 1, 2015. VAL-083 is a 'first-in-class', small-molecule chemotherapeutic. In more than 40 Phase 1 and 2 clinical studies sponsored by the National Cancer Institute, VAL-083 demonstrated safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia and lung cancer and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas. As a potential treatment for glioblastoma, VAL-083's mechanism of action appears to be unaffected by the expression of MGMT, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar (temozolomide). DelMar is currently studying multi-center VAL-083 in a Phase I/II clinical trial for patients with refractory glioblastoma multiforme in accordance with the protocol that has been filed with the U.S. Food and Drug Administration (FDA). Eligible GBM patients must have failed both Avastin (bevacizumab) and Temodar (temozolomide) unless either of these therapies was contraindicated.

DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 for Treatment of Non-Small Cell Lung Cancer at the American Association of Cancer Research Annual Meeting

DelMar Pharmaceuticals Inc. announced positive preclinical data on its lead product candidate VAL-083 (dianhydrogalactitol) for treatment of platinum drug-resistant non-small cell lung cancer (NSCLC) and as a potential combination therapy option in newly diagnosed NSCLC patients. VAL-083 is a 'first-in-class' bi-functional alkylating agent mediating inter-strand DNA crosslinks at N7 of guanine. VAL-083 has previously demonstrated activity against lung cancer in preclinical and clinical trials and is approved for treatment of lung cancer in China. The data was presented in a poster entitled, "In vitro activity of dianhydrogalactitol alone or with platinum drugs in the treatment of non-small cell lung cancer," at the 106th Annual Meeting of the American Association for Cancer Research (AACR), being held April 18-22, 2015, in Philadelphia, Pennsylvania. The purpose of this study was to investigate: the role of p53 status in the activity of VAL-083; VAL-083 activity in comparison to cisplatin and oxaliplatin; and the combination of VAL-083 with cisplatin or oxaliplatin. DelMar's study demonstrated that VAL-083's mechanism is distinct from platinum-based chemotherapy, the current standard of care for NSCLC. VAL-083 retains its high level of anti-cancer activity in p53 mutated NSCLC cell lines compared to cisplatin or oxaliplatin which provides support for the potential of VAL-083 as a viable treatment option for NSCLC patients failing platinum-based therapy. In addition, the combination of VAL-083 with either cisplatin or oxaliplatin demonstrated superadditivity/synergy against NSCLC cell lines, including those resistant to tyrosine kinase inhibitors. These results support the potential benefit of a VAL-083/platinum combination therapy in newly diagnosed NSCLC patients.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DMPI:US $0.81 USD +0.04

DMPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DMPI.
View Industry Companies

Industry Analysis


Industry Average

Valuation DMPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DELMAR PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at